24-27 November 2026Crocus Expo, Pavilion 2, Moscow
RU
Demand for CDMO pharmaceutical services is rising across the Eurasian market as manufacturers rebalance capacity and localise selected supply steps. Manufacturers are also moving products onto the Eurasian Economic Union (EAEU) regulatory framework. By May 2024, the Eurasian Economic Commission (EEC) reported that more than 15,000 medicine registration applications had been filed under Union rules. Additionally, about 5,700 marketing authorisations had been issued. For plant leaders and sourcing teams, outsourcing now depends as much on transfer speed and compliance control as on price.
A CDMO can cover active pharmaceutical ingredient (API) route work, excipient screening, formulation studies, analytical methods, pilot batches, scale-up, fill-finish manufacturing, packaging, stability studies, and release support. This matters because batch risk often begins upstream through material variability, incomplete technical files or weak data ownership.
Regulatory structure matters just as much as plant capacity. The World Health Organization (WHO) states that good manufacturing practice (GMP) covers responsibilities for contract manufacturing and testing. In the EAEU, the June 2024 guidance on GMP certificates provided member states with a common approach to completing and recognising production conformity certificates. This gives manufacturers using cross-border service models a clearer basis for supplier comparison.
For teams comparing providers across ingredients, equipment, and packaging, the pharmaceutical exhibition sector overview provides a quick overview of how contract services connect to the wider production chain.
The business case for outsourcing is operational. A good CDMO tests process capability early, builds method transfer into the project plan, and exposes failure modes before validation batches start. Research in the European Journal of Pharmaceutics and Biopharmaceutics showed that a batch-manufactured tablet could transfer to two continuous direct-compression lines while maintaining the original formulation and key quality attributes. When content uniformity drift was observed, investigators traced it to API micro-agglomerates and corrected the issue by adding a mill between the blenders.
The same rule applies in quality control. A 2025 systematic review found that production scale, temperature shifts, sample physical properties, and instrument changes are recurring sources of calibration drift in pharmaceutical analytics. For CDMO clients, that means analytical methods, instrument settings, and data review cycles need a transfer plan rather than a simple validation handover. Regional plant and lab updates also appear in Pharmtech's latest news.
The Eurasian market rewards suppliers that can work within local regulatory and operating conditions. The EEC reported in 2024 that application volumes under Union rules were rising, inspection activity and GMP certification were progressing, and participation from Union states outside Russia was growing. For buyers, this indicates a market with a broader pool of comparable suppliers working within a shared regulatory framework. That lowers friction during dossier work, site qualification and post-approval change handling.
One challenge is often missed. Outsourcing in the Commonwealth of Independent States (CIS) is not only about freight cost. It also depends on whether technical files, quality records, and release documentation move cleanly between the sponsor, the contract site, and the authorised release function. Small gaps in language control, specifications, data ownership or serialisation records can stall a programme long after scale-up.
The strongest regional CDMOs stand out because they narrow those gaps while giving clients shorter supplier lines and better audit access. For teams mapping the supply base, the pharma manufacturing expo overview and the main pharmtech expo portal can help identify which dosage forms and service categories are active in the market.
A strong outsourcing model compresses technical discovery into a single programme. Instead of running separate searches for API sourcing, excipient grades, process equipment, primary packaging, analytical methods, and release testing, the sponsor can compare options within a shared development path.
A sound CDMO assessment tests three points early:
A 2023 study on lyophilisation scale-up found that repeated manufacturing-scale experiments are costly and waste valuable drug product, whereas modelling reduces the risk of failure before full-scale runs. That is why pilot evidence, validation-ready documentation and realistic tech-transfer packages matter so much in supplier reviews. Those preparing to meet criteria can use pharma trade show resources to shape a shortlist by function and dosage form.
CDMOs and contract service providers can submit an exhibitor enquiry for the Contract Services zone at Pharmtech & Ingredients 2026, held from 24–27 November 2026 at Crocus Expo, Pavilion 2, Moscow. The event brings together manufacturers, quality leaders, and sourcing teams from across Eurasia. It offers direct access to discussions on scale-up, compliant supply, packaging, ingredients and commercial manufacturing partnerships.
